Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Mar has averaged the highest return (+25.4%); Jan the lowest (-34.5%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -34.5%Negative MonthJan 2026: -34.48% | +13.4%Positive MonthFeb 2026: +13.41% | +9.4%Positive MonthMar 2026: +9.41% | +18.1%Positive MonthApr 2026: +18.12% | +5.5%Positive MonthMay 2026: +5.46% | -10.0%Negative MonthJun 2026: -9.96% | +4.6%*Positive MonthJul 2026: +4.60% | β | β | β | β | β |
| 2025 | β | -21.4%Negative MonthFeb 2025: -21.40% | +41.3%Positive MonthMar 2025: +41.33% | -7.1%Negative MonthApr 2025: -7.13% | +19.1%Positive MonthMay 2025: +19.10% | +13.6%Positive MonthJun 2025: +13.56% | -10.3%Negative MonthJul 2025: -10.30% | -4.3%Negative MonthAug 2025: -4.29% | -2.7%Negative MonthSep 2025: -2.67% | +1.2%Neutral MonthOct 2025: +1.21% | -17.1%Negative MonthNov 2025: -17.11% | +17.7%Positive MonthDec 2025: +17.69% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 2 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.30 K Cr | β | βΉ19.00 Cr | β | β | 0.3% | 655.8% | -104.9% |
| Mar 2024 | βΉ172.00 Cr | β | βΉ-390.00 | β | β | -98.0% | 341.0% | -51.2% |
| Mar 2023 | βΉ39.00 Cr | β | βΉ-799.00 | β | β | -101.5% | -70.5% | 247.4% |
| Mar 2022 | βΉ132.00 Cr | β | βΉ-230.00 | β | β | -22.6% | 528.6% | 90.1% |
| Mar 2021 | βΉ21.00 Cr | β | βΉ-121.00 | β | β | -15.5% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue / Net Sales | 21 | 132 | 39 | 172 | 1,300 | 1,510 |
| Total Expenses | 93 | 228 | 156 | 254 | 930 | 992 |
| EBIT / Operating Profit | -72 | -96 | -117 | -82 | 370 | 518 |
| OPM % | -337% | -72% | -303% | -48% | 28% | 34% |
| Other Income | 1 | 4 | -525 | -143 | -95 | -83 |
| Finance Costs | 16 | 68 | 48 | 89 | 162 | 137 |
| Depreciation & Amortisation | 34 | 70 | 109 | 76 | 135 | 135 |
| Profit Before Tax | -121 | -230 | -799 | -390 | -22 | 163 |
| Tax % | 0% | 0% | 0% | 0% | -187% | - |
| Net Profit / PAT | -121 | -230 | -799 | -390 | 19 | 163 |
| EPS (βΉ) | - | - | - | - | 1.69 | 14.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Onesource Specialty Pharma Limitedthis co. | βΉ20.30 K Cr | βΉ1.30 K Cr | 76.80 | 3.40 | -92.42 | 655.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
